Paul Hudson, Sanofi CEO (Eric Piermont/AFP via Getty Images)

Af­ter some lengthy de­lays, Sanofi gets the FDA's OK for a rare dis­ease drug

More than 2 years af­ter Sanofi claimed an ear­ly piv­otal win for its new­ly-ac­quired rare dis­ease drug su­tim­limab, and more than a year since the FDA hand­ed back their ini­tial ap­pli­ca­tion due to un­ex­plained man­u­fac­tur­ing is­sues, the phar­ma gi­ant has bounced back with the ap­proval late on Fri­day.

Sanofi, which is un­der­go­ing both a facelift as well as a re­struc­tur­ing un­der CEO Paul Hud­son, cheered the news that reg­u­la­tors in the US have cleared the drug for cold ag­glu­tinin dis­ease, an af­flic­tion that trig­gers a rare form of ane­mia in pa­tients.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.